RVTY Revvity
FY2024 10-K
Revvity (RVTY) filed its fiscal year 2024 10-K annual report with the SEC on Feb 25, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business model: health science solutions delivering end-to-end workflows from discovery to diagnosis across Life Sciences and Diagnostics segments
- • New products FY 2024: BioLegend's TotalSeq™ PhenoCyte™ for scalable single-cell protein analysis; Cellometer™ Ascend automated cell counter; Phenologic.AI™ deep-learning software module
Management Discussion & Analysis
- • Revenue and profitability details not disclosed in provided section
- • No segment performance metrics available in provided text
Risk Factors
- • IRS audit and uncertain tax positions in foreign jurisdictions, with a $33.2 million increase in tax reserves in 2023
- • Ongoing foreign exchange risk, including a $24.0 million loss in 2023 cash proceeds held offshore
Financial SummaryXBRL
Revenue
$2.8B
Net Income
$270M
Operating Margin
12.6%
Net Margin
9.8%
ROE
3.5%
Total Assets
$12.4B
EPS (Diluted)
$2.20
Operating Cash Flow
$628M
Source: XBRL data from Revvity FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Revvity Annual Reports
Get deeper insights on Revvity
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.